Takeda received approval from the U.S. FDA for GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It can be used as induction therapy, which includes an induction dose followed by maintenance doses.  This milestone follows the recent FDA approval of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant...